Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.74 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.74 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.74 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPN | P05981 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1886343 | 0.90 | GRIA1 (0.59) | GRIA1GRIA3PDE4DSCN2AFGFR1 | |
| SCHEMBL1882780 | 0.90 | GRIA1 (0.77) | GRIA1GRIA3PDE4DSCN2ANPC1 | |
| Perampanel SCHEMBL29354621 | 0.86 | GRIA1 (1.00) | GRIA1GRIA3PDE4DGRM5MEN1 | |
| Perampanel SCHEMBL194370 | 0.86 | GRIA1 (1.00) | GRIA1GRIA3PDE4DGRM5MEN1 | |
| Perampanel SCHEMBL4214584 | 0.86 | GRIA1 (1.00) | GRIA1GRIA3PDE4DGRM5MEN1 | |
| Perampanel SCHEMBL2857277 | 0.86 | GRIA1 (1.00) | GRIA1GRIA3PDE4DGRM5MEN1 | |
| Perampanel SCHEMBL31069847 | 0.86 | GRIA1 (1.00) | GRIA1GRIA3PDE4DGRM5MEN1 | |
| Perampanel SCHEMBL29718723 | 0.86 | GRIA1 (1.00) | GRIA1GRIA3PDE4DGRM5MEN1 | |
| SCHEMBL1889102 | 0.85 | GRIA1 (0.82) | GRIA1GRIA3PDE4DGRM5MEN1 | |
| SCHEMBL1884881 | 0.85 | GRIA1 (0.82) | GRIA1GRIA3PDE4DGRM5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1300396-B1 | 1,2-DIHYDROPYRIDINE COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF | EISAI R&D MAN CO LTD (JP) | 2009-01-14 | — | — | EP | claimed |
| US-20050245581-A1 | 1, 2-Dihydropyridine compounds, manufacturing method thereof and use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | US | claimed |
| US-6949571-B2 | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof | EISAI CO., LTD. (JP) | 2005-09-27 | — | — | US | claimed |
| US-20040023973-A1 | 1,2-Dihydropyridine compounds, process for preparation of the same and use thereof | CATALYST PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | claimed |
| EP-1300396-A1 | 1,2-DIHYDROPYRIDINE COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF | Eisai Co., Ltd. (JP) | 2003-04-09 | — | — | EP | claimed |
| US-7939549-B2 | 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-10 | — | — | US | disclosed |
| EP-2254577-A1 | AMPA RECEPTOR ANTAGONISTS FOR EPILEPSY, MENTAL DISORDERS OR DEFICITS IN SENSORY ORGAN | Eisai R&D Management Co., Ltd. (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-20100297181-A1 | AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-25 | — | — | US | disclosed |
| US-20100256191-A1 | AMPA RECEPTOR ANTAGONISTS AND ZONISAMIDE FOR EPILEPSY | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100222354-A1 | AMPA Receptor Antagonists and Aldose Reductase Inhibitors for Neuropathic Pain | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-09-02 | — | — | US | disclosed |
| US-7759367-B2 | 1,2-dihydropiridin-2-one compounds such as 3-(2-cyanophenyl)-1-phenyl-5-(2-pyridyl)-1,2-dihydropyridin-2-one, used as immunomodulators or antiinflammatory agents, and for the prevention or treatment of neurodegenerative diseases, such as demyelinating disorders | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-07-20 | — | — | US | disclosed |
| US-20100179193-A1 | AMPA Receptor Antagonists and Zonisamide for Neuropathic Pain | EISAI R&D MANAGEMENT CO., LTD (JP) | 2010-07-15 | — | — | US | disclosed |
| WO-2006107859-A2 | DIHYDROPYRIDINE COMPOUNDS FOR NEURODEGENERATIVE DISEASES AND DEMENTIA | EISAI CO., LTD. (JP) | 2006-10-12 | — | — | WO | disclosed |
| US-20060100249-A1 | Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-20050245581-A1 | 1, 2-Dihydropyridine compounds, manufacturing method thereof and use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-6949571-B2 | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof | EISAI CO., LTD. (JP) | 2005-09-27 | — | — | US | disclosed |
| EP-1465626-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIHYDROPYRIDINONE COMPOUNDS AND AN IMMUNOREGULATORY OR AN ANTIINFLAMMATORY AGENT AND THEIR USES | Eisai Co., Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
| US-20040023973-A1 | 1,2-Dihydropyridine compounds, process for preparation of the same and use thereof | CATALYST PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | disclosed |
| WO-2003047577-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIHYDROPYRIDINONE COMPOUNDS AND AN IMMUNOREGULATORY OR AN ANTIINFLAMMATORY AGENT AND THEIR USES | EISAI CO LTD (JP) | 2003-06-12 | — | — | WO | disclosed |
| EP-1300396-A1 | 1,2-DIHYDROPYRIDINE COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF | Eisai Co., Ltd. (JP) | 2003-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023973-A1 | 1,2-Dihydropyridine compounds, process for preparation of the same and use thereof | GRIK1, GRIK2, GRIK4 | GRIA1 14/4885GRIA3 58/4885PDE4D 2584/4885 |
| US-20050245581-A1 | 1, 2-Dihydropyridine compounds, manufacturing method thereof and use thereof | GRIK1, GRIK2, GRIK5 | GRIA1 24/4885GRIA3 46/4885PDE4D 1607/4885 |
| US-20100256191-A1 | AMPA RECEPTOR ANTAGONISTS AND ZONISAMIDE FOR EPILEPSY | GRIK5, GABRE, GABRA5 | GRIA1 47/4885GRIA3 34/4885PDE4D 1445/4885 |
| US-20100179193-A1 | AMPA Receptor Antagonists and Zonisamide for Neuropathic Pain | CHRNA5, GRIN3A, CHRNA2 | GRIA1 70/4885GRIA3 60/4885PDE4D 1263/4885 |
| US-20060100249-A1 | Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses | QDPR, PMP22, MAG | GRIA1 449/4885GRIA3 663/4885PDE4D 679/4885 |
| US-20100222354-A1 | AMPA Receptor Antagonists and Aldose Reductase Inhibitors for Neuropathic Pain | AKR1B1, AKR1C1, AKR1C2 | GRIA1 24/4885GRIA3 56/4885PDE4D 2521/4885 |
| US-20100297181-A1 | AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ | GRIK5, GRIK4, GRIK1 | GRIA1 34/4885GRIA3 31/4885PDE4D 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.